- $458.35m
- $356.31m
- $3.48m
JPM downgrades Surrozen to 'underweight' rating
U.S. RESEARCH ROUNDUP-Amazon.com, BorgWarner, Cincor pharma
Brief: Surrozen Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Brief: Surrozen Presents Data On Two Lead Therapeutic Candidates At United European Gastroenterology (Ueg) Week
Brief: Surrozen Announces Strategic Partnership With Boehringer Ingelheim To Develop Wnt Agonist Szn-413 For People With Retinal Diseases
Brief: Surrozen Publishes Study In Translational Vision Science And Technology Demonstrating Promise Of Szn-413 In Preclinical Models Of Diabetic Retinopathy
Brief: Surrozen Reports Second Quarter 2022 Financial Results
Brief: Surrozen Initiates Dosing In Phase 1 Clinical Trial Of Szn-043 For Severe Alcoholic Hepatitis
Brief: Surrozen Presents Data On Lead Therapeutic Candidates At Digestive Disease Week
U.S. STOCKS ON THE MOVE-Target, Surrozen, Agilysys, Carvana
Surrozen surges on earlier-than-expected start to human clinical trials
Brief: Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Ulcerative Colitis
Brief: Surrozen Reports First Quarter 2022 Financial Results
Brief: Surrozen Inc Files For Offering Of 7 Mln Shares By Lincoln Park Capital Fund
Brief: Surrozen Reports Fourth Quarter And Full Year 2021 Financial Results
NASDAQ RESUMED AT 09:53 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:47 AM
NASDAQ RESUMED AT 09:46 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM